Duke logo

TBCRC039 (Inflammatory Triple Negative Breast Cancer) - Clinical Trial

What is the Purpose of this Study?

We are studying to see if the study drug, ruxolitinib, is a possible treatment for Inflammatory Breast Cancer.
The following drugs will be used with ruxolitinib:
- paclitaxel (also called Taxol)
- doxorubicin (also called Adriamycin)
- cyclophosphamide (also called Cytoxan)

What is the Condition Being Studied?

Triple Negative, Inflammatory Breast Cancer

Who Can Participate in the Study?

Both men and women above 18 years of age with triple negative, inflammatory breast cancer.

What is Involved?

If you join this study, you will get the study drug ruxolitinib plus the approved cancer drug paclitaxel. You will then get the standard chemotherapy drugs, doxorubicin and cyclophosphamide.

- Paclitaxel, doxorubicin, and cyclophosphamide are approved drugs for the treatment of breast cancer.

- A core needle biopsy of your breast tissue will be done before starting therapy.

- You will have tests, exams, and procedures that are part of your standard care and for study purposes.

Study Details

Full Title
Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer (DFCI 16-151/TBCRC039)
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00092397
NCT:NCT02876302
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698